Contrast-induced nephropathy (CIN) Consensus Working Panel: Executive summary

Reviews in Cardiovascular Medicine

Volumn 7, Issue 4, 2006, Pages 177-197

  McCullough, Peter A ^a   Stacul, Fulvio ^b   Becker, Christoph R ^c   Adam, Andy ^d   Lameire, Norbert ^e   Tumlin, James A ^f   Davidson, Charles J ^g  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF TRIESTE   (Italy)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Southeast Renal Research Institute SERRI   (United States)

^g NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Acute renal failure; Baseline renal function; Chronic kidney disease; Contrast induced nephropathy; Iodinated contrast media

Indexed keywords

AMINOPHYLLINE; ASCORBIC ACID; CAPTOPRIL; CISPLATIN; CREATINE KINASE; CREATININE; CYCLOSPORIN; DIATRIZOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOBITRIDOL; IODINATED CONTRAST MEDIUM; IODINE; IODIXANOL; IOHEXOL; IOMEPROL; IONIC CONTRAST MEDIUM; IOPAMIDOL; IOPENTOL; IOPROMIDE; IOTALAMIC ACID; IOVERSOL; IOXAGLIC ACID; IOXITALAMIC ACID; MEGLUMINE DIATRIZOATE PLUS SODIUM DIATRIZOATE; METRIZOIC ACID; NONIONIC CONTRAST MEDIUM; THEOPHYLLINE; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; AGING; ANEMIA; ANGIOCARDIOGRAPHY; AORTA BALLOON; CLINICAL TRIAL; CONSENSUS; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIALYSIS; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DRUG RETENTION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMAGE ENHANCEMENT; INCIDENCE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FUNCTION TEST; KIDNEY GRAFT; LIVER DISEASE; MEDICAL RESEARCH; META ANALYSIS; MORTALITY; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RADIOGRAPHY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; UREA NITROGEN BLOOD LEVEL;

CONTRAST MEDIA; HUMANS; INCIDENCE; KIDNEY FAILURE; WORLD HEALTH;

EID: 33846440115     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (202)

1. McCullough P, Stacul F, Davidson C, et al. Overview. Am J Cardiol. 2006;98(6 suppl 1):2-4.
2. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin. 2005;21:261-280.
3. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol. 2004;183:1673-1689.
4. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930-936.
5. McCullough PA, Adam A, Becker C, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98(6 suppl 1):5-13.
6. CIN Consensus Working Panel. Contrast-induced nephropathy: clinical insights and practical guidance. Am J Cardiol. 2006;98(6 suppl 1):1-78.
7. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003;76:513-518.
8. Fung JW, Szeto CC, Chan WW, et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis. 2004;43:801-808.
9. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol. 2004;62:1-7.
10. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148:422-429.
11. Kerstein MD, Puyau FA. Value of periangiography hydration. Surgery. 1984;96:919-922.
12. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol. 1981;136:859-861.
13. Campbell DR, Flemming BK, Mason WF, et al. A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. Can Assoc Radiol J. 1990;41:133-137.
14. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515-1519.
15. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
16. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003;15:18-22.
17. Bonser RS, Buckels JAC, Woodward DAK, Bullen BR. Athero-embolic renal failure after transfemoral aortography: a case report. Vasc Surg. 1985;19:439-442.
18. Vassalotti JA, Delgado FA, Whelton A. Atheroembolic renal disease. Am J Ther. 1996;3:544-549.
19. Thadhani RI, Camargo CA, Jr, Xavier RJ, et al. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Medicine (Baltimore). 1995;74:350-358.
20. Saklayen MG, Gupta S, Suryaprasad A, Azmeh W. Incidence of atheroembolic renal failure after coronary angiography. A prospective study. Angiology. 1997;48:609-613.
21. Hauben M, Norwich J, Shapiro E, et al. Multiple cholesterol emboli syndrome - six cases identified through the spontaneous reporting system. Angiology. 1995;46:779-784.
22. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996;275:1489-1494.
23. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
24. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-1548.
25. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769-2775.
26. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780-1785.
27. Lindsay J, Apple S, Pinnow EE, et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv. 2003;59:338-343.
28. Lindsay J, Canos DA, Apple S, et al. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB versus rise of serum creatinine. Am J Cardiol. 2004;94:786-789.
29. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13-19.
30. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90:1068-1073.
31. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
32. Martin-Paredero V, Dixon SM, Baker JD, et al. Risk of renal failure after major angiography. Arch Surg. 1983;118:1417-1420.
33. Gomes AS, Baker JD, Martin-Paredero V, et al. Acute renal dysfunction after major arteriography. AJR Am J Roentgenol. 1985;145:1249-1253.
34. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94:300-305.
35. Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98(6 suppl 1):14-20.
36. Wang YX, Jia YF, Chen KM, Morcos SK. Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol. 2001;74:1103-1108.
37. Liss P, Nygren A, Olsson U, et al. Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. Kidney Int. 1996;49:1268-1275.
38. Nygren A. Contrast media and regional renal blood flow. A study of the effects of ionic and non-ionic monomeric and dimeric contrast media in the rat. Acta Radiol Suppl. 1992;378:123-135.
39. Palm F, Carlsson PO, Fasching A, et al. Effects of the contrast medium iopromide on renal hemodynamics and oxygen tension in the diabetic rat kidney. Adv Exp Med Biol. 2003;530:653-659.
40. Moreau JF, Droz D, Noel LH, et al. Tubular nephrotoxicity of water-soluble iodinated contrast media. Invest Radiol. 1980;15(6 suppl):S54-S60.
41. Gruskin AB, Oetliker OH, Wolfish NM, et al. Effects of angiography on renal function and histology in infants and piglets. J Pediatr. 1970;76:41-48.
42. Dawson P, Freedman DB, Howell MJ, Hine AL. Contrast-medium-induced acute renal failure and Tamm-Horsfall proteinuria. Br J Radiol. 1984;57:577-579.
43. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol. 2002;15:336-341.
44. Scott JA, King GL. Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci. 2004;1031:204-213.
45. Schnackenberg CG. Oxygen radicals in cardiovascular-renal disease. Curr Opin Pharmacol. 2002;2:121-125.
46. Conesa EL, Valero F, Nadal JC, et al. N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol. 2001;281:R730-737.
47. Heyman SN, Goldfarb M, Shina A, et al. N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int. 2003;63:634-641.
48. Sandhu C, Newman DJ, Morgan R, et al. The role of oxygen free radicals in contrast induced nephrotoxicity. Acad Radiol. 2002;9(suppl 2):S436-S437.
49. Fiaccadori E, Maggiore U, Rotelli C, et al. Plasma and urinary free 3-nitrotyrosine following cardiac angiography procedures with non-ionic radiocontrast media. Nephrol Dial Transplant. 2004;19:865-869.
50. Drager LF, Andrade L, Barros de Toledo JF, et al. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant. 2004;19:1803-1807.
51. Jakobsen JA. Renal effects of iodixanol in healthy volunteers and patients with severe renal failure. Acta Radiol Suppl. 1995;399:191-195.
52. Yamazaki H, Oi H, Matshushita M, et al. Renal cortical retention of contrast medium on delayed CT and nephropathy following transcatheter arterial chemoembolisation in patients with high serum creatinine level. Br J Radiol. 2002;75:874-878.
53. Yamazaki H, Oi H, Matsushita M, et al. Renal cortical retention on delayed CT and nephropathy following transcatheter arterial chemoembolisation. Br J Radiol. 2001;74:695-700.
54. Yamazaki H, Oi H, Matsushita M, et al. Renal cortical retention on delayed CT after angiography and contrast associated nephropathy. Br J Radiol. 1997;70:897-902.
55. Rickards D, Jakobsen JA, Klaveness AJ, Kjaersgaard P. Delayed CT of the kidneys after iopentol (Imagopaque 350) injection in patients with normal renal function. An assessment of the gradual decrease in opacification over 32 h after injection. Eur Radiol. 1997;7(suppl 4):S149-S151.
56. Jakobsen JA, Berg KJ, Kjaersgaard P, et al. Angiography with nonionic X-ray contrast media in severe chronic renal failure: renal function and contrast retention. Nephron. 1996;73:549-556.
57. Love L, Olson MC. Persistent CT nephrogram: significance in the diagnosis of contrast nephropathy - an update. Urol Radiol. 1991;12:206-208.
58. Jakobsen JA, Lundby B, Kristoffersen DT, et al. Evaluation of renal function with delayed CT after injection of nonionic monomeric and dimeric contrast media in healthy volunteers. Radiology. 1992;182:419-424.
59. Love L, Johnson MS, Bresler ME, et al. The persistent computed tomography nephrogram: its significance in the diagnosis of contrast-associated nephrotoxicity. Br J Radiol. 1994;67:951-957.
60. Love L, Lind JA Jr, Olson MC. Persistent CT nephrogram: significance in the diagnosis of contrast nephropathy. Radiology. 1989;172:125-129.
61. Older RA, Korobkin M, Cleeve DM, et al. Contrast-induced acute renal failure: persistent nephrogram as clue to early detection. AJR Am J Roentgenol. 1980;134:339-342.
62. Weibull H, Tornquist C, Bergqvist D, et al. Reversible renal insufficiency after percutaneous transluminal angioplasty (PTA) of renal artery stenosis. Acta Chir Scand. 1984;150:295-300.
63. Lameire N, Adam A, Becker C, et al. Baseline renal function screening. Am J Cardiol. 2006;98(6 suppl 1):21-26.
64. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
65. Coresh J, Eknoyan G, Levey AS. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol. 2002;13:2811-2812.
66. Lee JK, Warshauer DM, Bush WH Jr, et al. Determination of serum creatinine level before intravenous administration of iodinated contrast medium. A survey. Invest Radiol. 1995;30:700-705.
67. McCullough PA, Adam A, Becker C, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(6 suppl 1):27-36.
68. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
69. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res. 2005;66:286-294.
70. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol. 1991;157:49-58.
71. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989;320:143-149.
72. Kamdar A, Weidmann P, Makoff D, Massry S. Radiography dye induced acute renal failure in diabetes mellitus [abstract]. Kidney Int. 1976;10:501.
73. Turcot DB, Kiernan FJ, McKay RG, et al. Acute hyperglycemia: implications for contrast-induced nephropathy during cardiac catheterization. Diabetes Care. 2004;27:620-621.
74. Steinberg EP, Moore RD, Brinker JA, et al. Nephrotoxicity of low osmolality contrast media versus high osmolality media. Invest Radiol. 1991;26(suppl 1):S86; discussion S88-S91.
75. Moore RD, Steinberg EP, Powe NR, et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology. 1992;182:649-655.
76. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005;67:706-713.
77. Alamartine E, Phayphet M, Thibaudin D, et al. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. Eur J Intern Med. 2003;14:426-431.
78. Louis BM, Hoch BS, Hernandez C, et al. Protection from the nephrotoxicity of contrast dye. Ren Fail. 1996;18:639-646.
79. Gupta RK, Kapoor A, Tewari S, et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J. 1999;51:521-526.
80. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol. 2005;148:107-121.
81. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460-464.
82. Oymak O. Contrast media induced irreversible acute renal failure in a patient treated with intraperitoneal cisplatin. Clin Nephrol. 1995;44:135-136.
83. Raynal-Raschilas N, Deray G, Bagnis C, Jacobs C. Severe acute renal failure after administration of contrast media in a patient treated with cisplatin. Nephrol Dial Transplant. 1996;11:2522-2523.
84. Thomsen HS, Dorph S, Larsen S, et al. Chronic cisplatin nephropathy, contrast media, and creatinine. Acad Radiol. 1996;3(suppl 2):S444-S446.
85. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med. 1995;332:647-655.
86. Swartz RD, Rubin JE, Leeming BW, Silva P. Renal failure following major angiography. Am J Med. 1978;65:31-37.
87. Najjar M, Hamad A, Salameh M, et al. The risk of radiocontrast nephropathy in patients with cirrhosis. Ren Fail. 2002;24:11-18.
88. Guevara M, Fernandez-Esparrach G, Alessandria C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology. 2004;40:646-651.
89. Huo TI, Wu JC, Huang YH, et al. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther. 2004;19:999-1007.
90. Huo TI, Wu JC, Lee PC, et al. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int. 2004;24:210-215.
91. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol. 1983;141:1027-1033.
92. Gussenhoven MJ, Ravensbergen J, van Bockel JH, et al. Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease. J Cardiovasc Surg (Torino). 1991;32:81-86.
93. Becker C, Davidson CJ, Lameire N, et al. High risk situations and procedures. Am J Cardiol. 2006;98(6 suppl 1):37-41.
94. Van Den Noortgate N, Mouton V, Lamot C, et al. Outcome in a post-cardiac surgery population with acute renal failure requiring dialysis: does age make a difference? Nephrol Dial Transplant. 2003;18:732-736.
95. Suen WS, Mok CK, Chiu SW, et al. Risk factors for development of acute renal failure (ARF) requiring dialysis in patients undergoing cardiac surgery. Angiology. 1998;49:789-800.
96. Provenchere S, Plantefeve G, Hufnagel G, et al. Renal dysfunction after cardiac surgery with normothermic cardiopulmonary bypass: incidence, risk factors, and effect on clinical outcome. Anesth Analg. 2003;96:1258-1264, table of contents.
97. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med. 1998;128:194-203.
98. Kashyap VS, Cambria RP, Davison JK, L'Italien GJ. Renal failure after thoracoabdominal aortic surgery. J Vasc Surg. 1997;26:949-955; discussion 955-957.
99. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology. 2001;34:1242-1251.
100. Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med. 1995;332:1192-1197.
101. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28:416-422.
102. Silva RF, Arroyo PC Jr, Duca WJ, et al. Complications following transjugular intrahepatic portosystemic shunt: a retrospective analysis. Transplant Proc. 2004;36:926-928.
103. Nakano R, Iwao T, Oho K, et al. Effect of transcatheter arterial chemoembolization on kidney hemodynamics and function in patients with cirrhosis and hepatocellular carcinoma. J Hepatol. 1999;31:340-346.
104. Deray G, Mouquet C, Ourhama S, et al. Effects on renal haemodynamics and tubular function of the contrast medium Ioxaglate in renal transplant patients. Clin Radiol. 1995;50:476-478.
105. Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. Clin Nephrol. 2000;54:11-14.
106. Hietala SO, Segerstedt B, Wirell S, et al. Effects of contrast media on renal graft function and survival after cerebral angiography of cadaveric donors. Acta Radiol. 1989;30:317-319.
107. Venkataraman V, Nolph KD. Preservation of residual renal function - an important goal. Perit Dial Int. 2000;20:392-395.
108. Singhal MK, Bhaskaran S, Vidgen E, et al. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int. 2000;20:429-438.
109. Davidson C, Stacul F, McCullough PA, et al. Contrast medium use. Am J Cardiol. 2006;98(6 suppl 1):42-58.
110. Alwall N, Erlanson P, Tornberg A. This clinical course of renal failure occurring after intravenous urography and/or retrograde pyelography; casuistics of 11 cases (including 7 deaths); on indications for and risks involved in the use of contrast media, including some remarks on the risk of aspiration biopsy of the kidney. Acta Med Scand. 1955;152:163-173.
111. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188:171-178.
112. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47:254-261.
113. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692-699.
114. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int. 2005;68:2256-2263.
115. Clauss W, Dinger J, Meissner C. Renal tolerance of iotrolan 280 - a meta analysis of 14 double-blind studies. Eur Radiol. 1995;5:S79-S84.
116. Fleischmann D. Use of high concentration contrast media: principles and rationale - vascular district. Eur J Radiol. 2003;45:S88-S93.
117. Cademartiri F, Luccichenti G, Marano R, et al. Spiral CT-angiography with one, four, and sixteen slice scanners. Technical note. Radiol Med (Torino). 2003;106:269-283.
118. Altmann D, Zwas D, Spatz A. Use of the contrast volume to estimated creatinine clearance ratio to predict renal failure after angiography. J Intervent Cardiol. 1997;10:113-119.
119. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990;89:615-620.
120. Chanard J, Jolly D, Doco J. Nephrotoxicity of conventional and low osmolality radiocontrast media. J Nephrol. 1991;4:203-209.
121. Krumlovsky F, Simon N, Santhanam S. Acute renal failure (ARF) secondary to administration of radiographic contrast material (RCM) [abstract]. Kidney Int. 1976;10:501.
122. Krumlovsky FA, Simon N, Santhanam S, et al. Acute renal failure. Association with administration of radiographic contrast material. JAMA. 1978;239:125-127.
123. Guitterez NV, Diaz A, Timmis GC, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol. 2002;15:349-354.
124. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002;62:1539-1549.
125. Stacul F, Adam A, Becker C, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98(6 suppl 1):59-77.
126. Byrd LH, Sherman RL, Stenzel KH, Rubin AL. Computerized tomography-induced acute renal failure. Arch Intern Med. 1979;139:491.
127. Chen WY, Yen TS, Cheng JT, et al. Acute renal failure following intravenous pyelography. Taiwan Yi Xue Hui Za Zhi. 1970;69:229-233.
128. Dudzinski PJ, Petrone AF, Persoff M, Callaghan EE. Acute renal failure following high dose excretory urography in dehydrated patients. J Urol. 1971;106:619-621.
129. Pillay VK, Robbins PC, Schwartz FD, Kark RM. Acute renal failure following intravenous urography in patients with long-standing diabetes mellitus and azotemia. Radiology. 1970;95:633-636.
130. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329-336.
131. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328-2334.
132. Krasuski RA, Beard BM, Geoghagan JD, et al. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003;15:699-702.
133. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114:1570-1574.
134. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93:C29-C34.
135. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333-1340.
136. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83:260-263, A265.
137. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int. 1994;45:1425-1431.
138. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant. 1999;14:1146-1149.
139. Gandhi MR, Brown P, Romanowski CA, et al. The use of theophylline, an adenosine antagonist in the prevention of contrast media induced nephrotoxicity. Br J Radiol. 1992;65:838.
140. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology. 2002;223:772-779.
141. Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol. 2003;91:1157-1162.
142. Kapoor A, Kumar S, Gulati S, et al. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant. 2002;17:1936-1941.
143. Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology. 1995;195:17-22.
144. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol. 1998;11:151-156.
145. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant. 2004;19:2747-2753.
146. Attallah N, Yassine L, Musial J, et al. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62:273-278.
147. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23:729-736.
148. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843-849.
149. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837-2842.
150. Gurkowski L, MacDougall M, Wiegmann T. Effects of misoprostol on contrast-induced renal dysfunction. Am J Ther. 1995;2:837-842.
151. Koch JA, Plum J, Grabensee B, Modder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant. 2000;15:43-49.
152. Sketch MH, Jr, Whelton A, Schollmayer E, et al. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther. 2001;8:155-162.
153. Agrawal M, Wodlinger AM, Huggins CE, et al. Effect of N-acetylcysteine on serum creatinine concentration in patients with chronic renal insufficiency who are undergoing coronary angiography. Heart Drug. 2004;4:87-91.
154. Allaqaband S, Tumuluri R, Malik A, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002;57:279-283.
155. Azmus AD, Gottschall C, Manica A, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol. 2005;17:80-84.
156. Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114-2118.
157. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv. 2003;58:336-341.
158. Briguori C, Colombo A, Airoldi F, et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2004;44:762-765.
159. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25:206-211.
160. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40:298-303.
161. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89:356-358.
162. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202-2207.
163. Efrati S, Dishy V, Averbukh M, et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int. 2003;64:2182-2187.
164. Gill NK, Piccione EA, Vido DA, et al. Gender as a risk factor for contrast nephropathy: effects of hydration and N-acetylcysteine. Clin Cardiol. 2004;27:554-558.
165. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004;25:212-218.
166. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289:553-558.
167. Kefer JM, Hanet CE, Boitte S, et al. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol. 2003;58:555-560.
168. MacNeill BD, Harding SA, Bazari H, et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv. 2003;60:458-461.
169. Miner SE, Dzavik V, Nguyen-Ho P, et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004;148:690-695.
170. Ochoa A, Pellizzon G, Addala S, et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol. 2004;17:159-165.
171. Oldemeyer JB, Biddle WP, Wurdeman RL, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146:E23.
172. Rashid ST, Salman M, Myint F, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40:1136-1141.
173. Raven QL, Walton T, Howe AM, Macon EJ. Role of acetylcysteine in the prevention of contrast-media-induced nephrotoxicity. Am J Health Syst Pharm. 2003;60:2232-2235.
174. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383-1388.
175. Tadros GM, Mouhayar EN, Akinwande AO, et al. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol. 2003;15:311-314.
176. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-184.
177. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65:1366-1374.
178. Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis. 2004;43:1-9.
179. Guru V, Fremes SE. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol. 2004;62:77-83.
180. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol. 2003;92:1454-1458.
181. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med. 2004;2:38.
182. Misra D, Leibowitz K, Gowda RM, et al. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol. 2004;27:607-610.
183. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15:761-769.
184. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective
185. Hoffmann U, Fischereder M, Krueger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407-410.
186. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol. 1999;34:1682-1688.
187. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284-2291.
188. Cacoub P, Deray G, Baumelou A, Jacobs C. No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. Clin Nephrol. 1988;29:215-216.
189. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995;15:59-65.
190. Russo D, Testa A, Della Volpe L, Sansone G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron. 1990;55:254-257.
191. Carraro M, Mancini W, Artero M, et al. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant. 1996;11:444-448.
192. Madsen JK, Jensen JW, Sandermann J, et al. Effect of nitrendipine on renal function and on hormonal parameters after intravascular iopromide. Acta Radiol. 1998;39:375-380.
193. Neumayer HH, Junge W, Kufner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant. 1989;4:1030-1036.
194. Spangberg-Viklund B, Berglund J, Nikonoff T, et al. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol. 1996;30:63-68.
195. Arici M, Usalan C, Altun B, et al. Radiocontrast-induced nephrotoxicity and urinary alphaglutathione S-transferase levels: effect of amlodipine administration. Int Urol Nephrol. 2003;35:255-261.
196. Kurnik BR, Weisberg LS, Cuttler IM, Kurnik PB. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. J Lab Clin Med. 1990;116:27-36.
197. Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31:674-680.
198. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45:259-265.
199. Miller HI, Dascalu A, Rassin TA, et al. Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol. 2003;23:91-95.
200. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol. 1999;33:403-411.
201. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
202. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 2000;57:1675-1680.